These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26665779)

  • 41. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
    Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
    Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.
    Shin JH; Choo MS
    Low Urin Tract Symptoms; 2019 May; 11(3):151-157. PubMed ID: 30623583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
    Mullen GR; Kaplan SA
    Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O180-O185. PubMed ID: 30565417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.
    Freemantle N; Ginsberg DA; McCool R; Fleetwood K; Arber M; Khalaf K; Loveman C; Ni Q; Glanville J
    BMJ Open; 2016 Feb; 6(2):e009122. PubMed ID: 26908514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mirabegron: A Review in Overactive Bladder Syndrome.
    Deeks ED
    Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
    Kashyap M; Tyagi P
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):617-27. PubMed ID: 23550899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.
    Shen YC; Wang HJ; Chuang YC
    Int Urol Nephrol; 2018 Jul; 50(7):1219-1226. PubMed ID: 29882001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mirabegron (Myrbetriq) for overactive bladder.
    Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
    [No Abstract]   [Full Text] [Related]  

  • 56. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
    Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
    Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
    Bridgeman MB; Friia NJ; Taft C; Shah M
    Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
    Sharaf A; Hashim H
    Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Griebling TL
    J Urol; 2015 Mar; 193(3):947. PubMed ID: 25765412
    [No Abstract]   [Full Text] [Related]  

  • 60. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.